Related Experiment Video
Updated: Aug 6, 2026
12:21
A Versatile Automated Platform for Micro-scale Cell Stimulation Experiments
Published on: August 6, 2013
A singular base-editing platform for polyfunctional multiplex engineering of immune cells
Joseph G Skeate1, Nicholas J Slipek1, Walker S Lahr1
1Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; Center for Genome Engineering, University of Minnesota, Minneapolis, MN, USA.
Summary
This study introduces INSERT, a novel method for engineering CAR T cells. It safely and efficiently generates off-the-shelf CAR T cells with enhanced anti-cancer function in a single step.
Area of Science:
- Biotechnology
- Molecular Biology
- Immunotherapy
Background:
- Current CAR T cell engineering methods face safety challenges due to random vector integration or double-strand break induction.
- Targeted integration and multiplex gene editing are crucial for developing safer and more effective off-the-shelf cell therapies.
Purpose of the Study:
- To develop a simplified and safe platform for multiplex gene editing and chimeric antigen receptor (CAR) insertion into specific genomic loci.
- To enhance homology-directed repair (HDR) efficiency for CAR T cell engineering using base editor nickase activity.
Main Methods:
- Utilized a novel single-guide RNA design and recombinant adeno-associated virus delivery for efficient base editor (ABE8e)-stimulated HDR.
- Implemented a quadplex gene knockout (KO) strategy targeting B2M, CD3E, PDCD1, and CISH genes.
- Performed knockin (KI) of CD19, CD33, or mesothelin-targeting CARs into human T cells.
Main Results:
- Achieved efficient single-step generation of CAR T cells with >95% quadplex gene KO and CAR KI.
- Demonstrated enhanced CAR T cell function against multiple cancer cell lines and a 3D spheroid model.
- Confirmed no detectable translocations or significant off-target edits, indicating a high safety profile.
Conclusions:
- The developed INSERT (Iterative Nicking for Synchronous Engineered Reprogramming of T cells) platform offers a safe and simplified approach for advanced therapeutic CAR T cell engineering.
- This method enables the creation of highly functional, off-the-shelf CAR T cell products with improved safety and efficacy.
- The technology holds promise for advancing the clinical application of CAR T cell therapies.
